Candel Therapeutics, Inc.

CADL Nasdaq CIK: 0001841387

Company Information

Industry Biological Products, (No Diagnostic Substances)
SIC Code 2836
Entity Type operating
SEC Category Non-accelerated filerSmaller reporting companyEmerging growth company
State of Incorporation DE
Business Address 117 KENDRICK STREET, NEEDHAM, MA, 02494
Mailing Address 117 KENDRICK STREET, NEEDHAM, MA, 02494
Phone 617-916-5445
Fiscal Year End 1231
EIN 522214851

Financial Overview

FY2025

$73.27M
Total Liabilities

Recent SEC Filings

Form Type Date Filed Document
4 Insider stock transaction report April 2, 2026 View on SEC
4 Insider stock transaction report April 2, 2026 View on SEC
4 Insider stock transaction report April 2, 2026 View on SEC
SCHEDULE 13D/A Beneficial ownership amendment March 18, 2026 View on SEC
8-K Current report of material events March 12, 2026 View on SEC
10-K Annual financial report March 12, 2026 View on SEC
4 Insider stock transaction report February 26, 2026 View on SEC
8-K Current report of material events February 23, 2026 View on SEC
424B5 Prospectus supplement February 20, 2026 View on SEC
8-K Current report of material events February 19, 2026 View on SEC

Annual Reports

10-K March 12, 2026
  • Advancing two lead viral immunotherapy candidates, CAN-2409 and Linoserpaturev, for major cancers.
  • CAN-2409 shows encouraging interim data in prostate cancer and is in pivotal Phase 2/3 for pancreatic cancer.
View Analysis

Insider Trading

BUY 1 insiders 1 recent transactions
View Full Insider Trading Profile

Related Companies

Companies in the same industry (SIC: 2836)

Investor Resources

Learn more about SEC filings and how to research public companies.

Important Disclaimer

This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.